News/ Pharma Market Access/ UK & Europe NICE backs £220,000-a-year Duchenne drug following discount Richard Staines Duchenne, Highly Specialised Technology appraisals, PTC Therpeutics 0 Comment The National Health Service should fund PTC Therapeutics’ Duchenne Muscular Dystrophy drug, Translarna (ataluren), NICE has said, after Share X NICE backs £220,000-a-year Duchenne drug following discount https://pharmaphorum.com/news/nice-backs-ptc-muscular-dystrophy-drug-following-discount/
Duchenne, Highly Specialised Technology appraisals, PTC Therpeutics
0 Comment
